ALK-positivity rates in the present study, 2.8% in the whole population and 5.1% in the group of EGFR and KRAS mutation-negative adenocarcinomas are consistent with those obtained in the many previous studies. The gene discussed is KRAS; the disease is adenocarcinoma.